(-0.13%) 5 462.13 points
(-0.32%) 38 987 points
(0.15%) 17 745 points
(0.43%) $81.18
(-3.48%) $2.66
(-0.84%) $2 311.20
(-0.22%) $28.81
(1.63%) $1 002.50
(0.28%) $0.936
(0.73%) $10.68
(0.39%) $0.791
(-0.21%) $87.31
Live Chart Being Loaded With Signals
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases...
Stats | |
---|---|
本日の出来高 | 75 412 |
平均出来高 | 193 348 |
時価総額 | 49.07M |
EPS | $-0.460 ( Q1 | 2024-05-09 ) |
次の収益日 | ( $-0.360 ) 2024-08-08 |
Last Dividend | $0.361 ( 2023-03-08 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.050 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00600 (0.50%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-17 | Morris Richard Steven | Buy | 85 000 | Stock Option (Right to Buy) |
2024-06-17 | Klichinsky Michael | Buy | 85 000 | Stock Option (Right to Buy) |
2024-06-17 | Kelly Steven | Buy | 125 000 | Stock Option (Right to Buy) |
2024-04-01 | Hohneker John | Buy | 38 700 | Stock Option (Right to Buy) |
2024-04-01 | Hohneker John | Buy | 0 |
INSIDER POWER |
---|
100.00 |
Last 7 transactions |
Buy: 1 112 700 | Sell: 0 |
ボリューム 相関
Carisma Therapeutics, 相関
10 最も負の相関 | |
---|---|
JAJWX | -0.955 |
DTI | -0.944 |
ATMV | -0.94 |
CNRLX | -0.94 |
NEOV | -0.928 |
OCMAX | -0.928 |
IROH | -0.925 |
FORL | -0.922 |
QTTB | -0.92 |
ISRL | -0.919 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Carisma Therapeutics, 相関 - 通貨/商品
Carisma Therapeutics, 財務諸表
Annual | 2023 |
収益: | $14.92M |
総利益: | $6.65M (44.60 %) |
EPS: | $-2.59 |
FY | 2023 |
収益: | $14.92M |
総利益: | $6.65M (44.60 %) |
EPS: | $-2.59 |
FY | 2022 |
収益: | $9.83M |
総利益: | $3.74M (38.07 %) |
EPS: | $-575.42 |
Financial Reports:
No articles found.
Carisma Therapeutics, Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.361 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.361 | 2023-03-08 |
Last Dividend | $0.361 | 2023-03-08 |
Next Dividend | $0 | N/A |
Payout Date | 2023-03-08 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.361 | -- |
Avg. Dividend % Per Year | 0.94% | -- |
Score | 0.39 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.361 | 2.82% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
08 Mar 2023 | $0.361 | 03 Feb 2023 | 07 Mar 2023 | 08 Mar 2023 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -5.39 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.101 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.16 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.42 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.30 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.102 | -1.500 | 8.31 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -103.61 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.911 | 2.00 | -0.637 | -1.274 | [0 - 30] |
freeCashFlowPerShareTTM | -1.935 | 2.00 | -0.968 | -1.935 | [0 - 20] |
debtEquityRatioTTM | 0.688 | -1.500 | 7.25 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.656 | 1.000 | 2.40 | 2.40 | [0.2 - 0.8] |
operatingProfitMarginTTM | -5.66 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -10.44 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.204 | 0.800 | -1.972 | -1.577 | [0.5 - 2] |
Total Score | -1.801 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.580 | 1.000 | -0.160 | 0 | [1 - 100] |
returnOnEquityTTM | -2.16 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.935 | 2.00 | -0.645 | -1.935 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.911 | 2.00 | -0.637 | -1.274 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0261 | 1.500 | -3.51 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -5.19 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.80 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Carisma Therapeutics,
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。